Immix Biopharma (IMMX) Set to Release Earnings on Friday

Immix Biopharma (NASDAQ:IMMX) is projected to post its Q3 2026 resultson Friday, November 6th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Immix Biopharma (NASDAQ:IMMX) last posted its earnings results on Friday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). On average, analysts expect Immix Biopharma to post ($0.76) EPS for the current fiscal year and ($0.86) EPS for the next fiscal year.

Immix Biopharma Stock Performance

Shares of IMMX stock opened at $7.97 on Thursday. The company has a market capitalization of $570.17 million, a price-to-earnings ratio of -9.06 and a beta of 0.29. The company has a 50-day simple moving average of $10.65 and a 200 day simple moving average of $9.48. Immix Biopharma has a 52 week low of $2.85 and a 52 week high of $15.10.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on IMMX shares. Citigroup restated a “market outperform” rating on shares of Immix Biopharma in a research report on Wednesday, September 30th. Mizuho set a $23.00 target price on Immix Biopharma in a research report on Thursday, October 29th. Morgan Stanley reiterated an “overweight” rating on shares of Immix Biopharma in a research note on Tuesday, October 20th. Needham & Company LLC lifted their price target on Immix Biopharma from $21.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, September 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, October 15th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.86.

Immix Biopharma Company Profile

Immix Biopharma, Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with difficult-to-treat cancers and other serious diseases. The company’s research and development activities are centered on engineered immune-cell treatments intended to target malignant cells.

Its lead product candidate is NXC-201, an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy designed to target B-cell maturation antigen (BCMA). NXC-201 is being evaluated in clinical studies for relapsed or refractory multiple myeloma and relapsed or refractory AL amyloidosis, a rare blood disorder in which abnormal plasma cells produce misfolded proteins.

Immix Biopharma was founded in 2012 and is headquartered in Los Angeles, California.